MIST: Milestone Pharmaceuticals Inc. Stock

by  •  • Comments Off on MIST: Milestone Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 104.13
Enterprise Value ($M) 140.14
Book Value ($M) 16.77
Book Value / Share 0.27
Price / Book 6.21
NCAV ($M) 14.58
NCAV / Share 0.23
Price / NCAV 7.14

Profitability (mra)
Return on Invested Capital (ROIC) -0.87
Return on Assets (ROA) -0.54
Return on Equity (ROE) -1.11

Liquidity (mrq)
Quick Ratio 10.11
Current Ratio 10.11

Balance Sheet (mrq) ($M)
Current Assets 73.03
Assets 75.23
Liabilities 58.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1.00
Operating Income -61.10
Net Income -59.69
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -46.42
Cash from Investing 4.76
Cash from Financing 47.79

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Rtw Investments, Lp 9.99 -22.25
02-14 13G/A Venrock Healthcare Capital Partners III, L.P. 2.80 -58.12
02-09 13G/A Goldman Sachs Group Inc 4.10 -50.57
01-29 13G/A Integrated Core Strategies (us) Llc 5.20 -21.15
01-24 13G/A BlackRock Inc. 9.80 89.30
11-09 13D Alta Fundamental Advisers LLC 5.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ¨ TRAN
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2023-05-31 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ¨ TRAN
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-03 17,108 85,360 20.04
2024-05-02 26,934 19,961 134.93
2024-05-01 14,923 20,227 73.78
2024-04-30 34,079 38,358 88.84

(click for more detail)

Similar Companies
ME – 23andMe Holding Co. MGNX – MacroGenics, Inc.
MGTX – MeiraGTx Holdings plc MLYS – Mineralys Therapeutics, Inc.
MNMD – Mind Medicine (MindMed) Inc.


Financial data and stock pages provided by
Fintel.io